Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999, 161: 182-187. 10.1016/S0022-5347(01)62092-5.
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000, 6: 2702-2706.
Wise GJ, Marella VK, Talluri G, Shirazian D: Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000, 164: 722-725. 10.1016/S0022-5347(05)67289-8.
Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992, 52: 3317-3322.
Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995, 71: 354-356. 10.1038/bjc.1995.71.
De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G: Serum levels of interleukin 6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep. 1998, 5: 649-652.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004, 291: 585-590. 10.1001/jama.291.5.585.
Nozoe T, Mori E, Takahashi I, Ezaki T: Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today. 2008, 38: 597-602. 10.1007/s00595-007-3680-8.
Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 2007, 107: 114-117. 10.1016/j.ygyno.2007.06.001.
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K: A prognostic index in primary breast cancer. Br J Cancer. 1982, 45: 361-366. 10.1038/bjc.1982.62.
Duffy SW, Taba'r L, Fagerberg G, Gad A, South MC, Day NE: Breast screening, prognostic factors and survival--results from the Swedish two county study. Br J Cancer. 1991, 64: 1133-1138. 10.1038/bjc.1991.477.
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 539 have been followed up for 15 years. Br J Cancer. 1957, 11: 359-377. 10.1038/bjc.1957.43.
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987, 56: 489-492. 10.1038/bjc.1987.230.
Lonn U, Lonn S, Nilsson B, Stenkvist B: Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat. 1994, 29: 237-245. 10.1007/BF00666477.
Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD: P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer. 2002, 100: 290-296. 10.1002/ijc.10478.
Malmstrom P, Bendahl PO, Boiesen N, Brünner N, Idvall I, Fernö M: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histological grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol. 2000, 19: 2010-2019.
Taba'r L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet. 2000, 355: 429-433.
Taba'r L, Duffy SW, Vitak B, Chen HH, Prevost TC: The natural history of breast carcinoma: what have we learned from screening?. Cancer. 1999, 86: 449-462.
Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996, 271: 736-741. 10.1074/jbc.271.2.736.
Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol. 2006, 12: 4473-4477.